SCHEDULE: Park Ha Biological Stakeholder Update

Nexera Technology and Jie Cao report a 9.1% stake in Park Ha Biological, including shares from upcoming warrant exercises.

Summary

• Nexera Technology Company Limited and Jie Cao have jointly filed a Schedule 13G, indicating their beneficial ownership of Park Ha Biological Technology Co., Ltd. Class A Ordinary Shares.
• The reporting persons collectively own 390,000 shares, representing 9.1% of the class of securities.
• This ownership includes 240,000 shares underlying warrants that are exercisable within the next 60 days.
• The filing is based on a total of 2,297,902 Class A Ordinary Shares outstanding after a reverse stock split effective August 6, 2026, plus the shares from the exercisable warrants.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing, primarily due to the disclosure of a significant warrant exercise that could dilute existing shareholders, without immediate positive operational news.

Positives

• The filing clearly discloses the beneficial ownership of Nexera Technology Company Limited and Jie Cao.
• The reporting persons have sole voting and dispositive power over their 390,000 shares.

Negatives

• The disclosure indicates that a significant number of shares (240,000) are held via warrants exercisable within 60 days, suggesting potential future dilution for existing shareholders.
• The filing does not provide any new operational or financial performance data for Park Ha Biological Technology Co., Ltd.

Risks

• Potential dilution of existing shareholders' equity due to the exercise of warrants for 240,000 Class A Ordinary Shares within the next 60 days.
• The concentration of ownership by Nexera Technology and Jie Cao could influence control or strategic decisions of Park Ha Biological Technology Co., Ltd.

Future Outlook

The filing indicates that warrants for 240,000 Class A Ordinary Shares are exercisable within the next 60 days, which could impact the share structure.

Management Comments

• "Includes 240,000 Class A Ordinary Shares for which Warrants are exercisable within the next 60 days."
• "Based on (i) 2,297,902 Class A Ordinary Shares outstanding following the effectiveness of the reverse stock split on August 6, 2026, as set forth in the Issuer's Form 6-K filed with the Securities and Exchange Commission ("SEC") on August 3, 2026 plus (ii) 2,000,000 Class A Ordinary Shares underlying a warrant which is exercisable within the next 60 days."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and significant shareholders to report their holdings. The mention of exercisable warrants highlights a common mechanism for potential equity dilution or future capital infusion, which is a standard consideration in biotechnology and technology sectors.

Stakeholder Impact

• Shareholders: Potential dilution of ownership percentage and voting power if warrants are exercised.
• Management of Park Ha Biological Technology Co., Ltd.: May need to consider the implications of increased ownership and potential warrant exercise on company strategy and control.

Next Steps

• Monitoring the exercise of warrants for 240,000 Class A Ordinary Shares within the next 60 days.
• Observing any further filings or announcements from Park Ha Biological Technology Co., Ltd. regarding its operational or financial performance.

Key Dates

Keywords

Schedule 13G, Beneficial Ownership, Park Ha Biological Technology, Nexera Technology, Jie Cao, Class A Ordinary Shares, Warrants, Shareholder Dilution